Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04526054 |
Recruitment Status :
Completed
First Posted : August 25, 2020
Last Update Posted : August 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Olfaction Disorders COVID-19 | Diagnostic Test: ENT exam Diagnostic Test: Olfactometry Diagnostic Test: Brain MRI | Not Applicable |
Several medical teams have recently shown that disturbances of smell and taste are common and can be a precursor and even an isolated sign of COVID-19 involvement. Preliminary results suggest the presence of clinical MRI abnormalities, particularly in the olfactory bulbs in anosmic patients with COVID-19.
Anosmia and taste disturbance are early warning signs that could be important in improving the detection and diagnosis of COVID-19, and also in monitoring disease. In addition, disturbances in smell and taste could be an aid in establishing the prognosis of the clinical course of the viral disease. The question of olfactory recovery is also fundamental. To date, we do not know the possibilities of recovery from COVID-19 post viral anosmia. ENT exams, olfactometry and MRI are proposed to study these phenomena.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients |
Actual Study Start Date : | September 3, 2020 |
Actual Primary Completion Date : | September 3, 2021 |
Actual Study Completion Date : | September 3, 2021 |

Arm | Intervention/treatment |
---|---|
anosmic or normosmic COVID-19 patients
Patients will undergo ENT exams, olfactometry and MRI.
|
Diagnostic Test: ENT exam
ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy. Diagnostic Test: Olfactometry Olfactometry test using odorous pens (Sniffin's stick test). Diagnostic Test: Brain MRI Brain MRI focused on the olfactory bulbs (3 teslas). |
- To compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by MRI on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. [ Time Frame: initial examination ]Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner.
- To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. [ Time Frame: initial examination ]Sniffin' test score (T threshold score, D discrimination score, I identification score).
- Longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on MRI in in COVID-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months. [ Time Frame: initial examination, 6 week to 2 months, 6 to 9 months ]Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner at initial examination, between 6 weeks and 2 months and between 6 and 9 months.
- To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. [ Time Frame: initial examination, 6 week to 2 months, 6 to 9 months ]Sniffin' test score (T threshold score, D discrimination score, I identification score).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient aged 18 or over
- Patient with or without a sense of smell diagnosed with a positive COVID-19 PCR test by nasopharyngeal swab in one of the investigation centers
- Patient who has already undergone cerebral MRI and olfactometry, as part of their routine care, within 3 days of being diagnosed with COVID-19+ or who agrees to undergo cerebral MRI and olfactometry within 3 days of being diagnosed with COVID-19+.
- Patient who signed a consent form
- Patient being affiliated to a Health Insurance plan
Exclusion Criteria:
- History of chronic rhino-sinusitis with or without polyp (s)
- History of major craniofacial trauma that led to loss of smell
- History of chronic sense of smell
- Diagnosis of Parkinson's disease or Alzheimer's disease
- Refusal to perform the 3 MRIs
- Refusal to participate in the study
- Pregnant, parturient or lactating woman
- Patient with contraindications to performing MRI
- Patient not speaking or understanding French
- Patient deprived of liberty or under guardianship

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04526054
France | |
Hopital Foch | |
Suresnes, Ile-de-France, France, 92150 | |
Hopital Raymond Poincare | |
Garches, France, 92380 |
Study Director: | Stephane Hans, Pr | Hopital Foch, Suresnes | |
Principal Investigator: | Robert-Yves Carlier, Pr | Hopital Raymond Poincare, Garches | |
Principal Investigator: | Jerome Lechien, Dr | Hopital Foch, Suresnes |
Responsible Party: | Hopital Foch |
ClinicalTrials.gov Identifier: | NCT04526054 |
Other Study ID Numbers: |
2020_0057 |
First Posted: | August 25, 2020 Key Record Dates |
Last Update Posted: | August 3, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
anosmia smell disorder COVID-19 MRI |
COVID-19 Olfaction Disorders Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections |
Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |